Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study

EBioMedicine

Volumn 5, Issue , 2016, Pages 105-113

  Xu, Zhi Peng ^a,b,c   Yang, Su Lian ^c   Zhao, Shi ^d   Zheng, Cheng Hong ^e   Li, Hong Hua ^b   Zhang, Yao ^c   Huang, Rong Xi ^a,c   Li, Meng Zhu ^a,c   Gao, Yuan ^a,c   Zhang, Shu Juan ^a,c   Zhan, Pei Yan ^d   Zhang, Li Fang ^e   Deng, Lin ^d   Wei, Sheng ^c   Liu, Yan Chao ^a,c   Ye, Jing Wang ^a,c   Ren, Hu Jun ^b   Li, Na ^d   Kong, Cai Xia ^f   Wang, Xin ^a,c   Fang, Lin ^a,c   Zhou, Qiu Zhi ^a,c   Jiang, Hong Wei ^c   Li, Jing Rong ^g   Wang, Qun ^a,c,h   Ke, Dan ^a,c,h   Liu, Gong Ping ^a,c,h   Wang, Jian Zhi ^a,h   more..

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d CENTRAL HOSPITAL OF WUHAN   (China)

^e HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^f First Hospital of Wuhan   (China)

^g Health Service Center of Jianghan District   (China)

^h NANTONG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; ApoE gene; Glycogen synthase kinase 3 ; Mild cognitive impairment; Olfactory score; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; GLYCOGEN SYNTHASE KINASE 3BETA; APOLIPOPROTEIN E4;

AGE; ALLELE; ARTICLE; CASE CONTROL STUDY; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DOT HYBRIDIZATION; EARLY DIAGNOSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SMELLING; WESTERN BLOTTING; AGED; ALZHEIMER DISEASE; BLOOD; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLICATION; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; THROMBOCYTE;

AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BIOMARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; COGNITIVE DYSFUNCTION; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84957617207     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.02.014     Document Type: Article

References (52)

1. Arvanitakis Z., Wilson R.S., Bienias J.L., et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 2004, 61(5):661-666.
2. Attems J., Walker L., Jellinger K.A. Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol. 2014, 127(4):459-475.
3. Ballard C., Gauthier S., Corbett A., et al. Alzheimer's disease. Lancet 2011, 377(9770):1019-1031.
4. Bertram L., Lill C.M., Tanzi R.E. The genetics of Alzheimer disease: back to the future. Neuron 2010, 68(2):270-281.
5. Biessels G.J., Deary I.J., Ryan C.M. Cognition and diabetes: a lifespan perspective. Lancet Neurol. 2008, 7(2):184-190.
6. Bocchetta M., Galluzzi S., Kehoe P.G., et al. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. Alzheimers Dement. 2015, 11(2):195-206.
7. Caroli A., Frisoni G.B., Alzheimer's Disease Neuroimaging, Initiative The dynamics of Alzheimer's disease biomarkers in the Alzheimer's disease neuroimaging initiative cohort. Neurobiol. Aging 2010, 31(8):1263-1274.
8. Christen-Zaech S., Kraftsik R., Pillevuit O., et al. Early olfactory involvement in Alzheimer's disease. Can. J. Neurol. Sci. 2003, 30(1):20-25.
9. Corder E.H., Saunders A.M., Strittmatter W.J., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261(5123):921-923.
10. Devanand D.P., Michaels-Marston K.S., Liu X., et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am. J. Psychiatry 2000, 157(9):1399-1405.
11. Devanand D.P., Pelton G.H., Zamora D., et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch. Neurol. 2005, 62(6):975-980.
12. Devanand D.P., Tabert M.H., Cuasay K., et al. Olfactory identification deficits and MCI in a multi-ethnic elderly community sample. Neurobiol. Aging 2010, 31(9):1593-1600.
13. Djordjevic J., Jones-Gotman M., De Sousa K., Chertkow H. Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2008, 29(5):693-706.
14. Donohoe G.G., Salomaki A., Lehtimaki T., Pulkki K., Kairisto V. Rapid identification of apolipoprotein E genotypes by multiplex amplification refractory mutation system PCR and capillary gel electrophoresis. Clin. Chem. 1999, 45(1):143-146.
15. El Haouari M., Rosado J.A. Platelet function in hypertension. Blood Cells Mol. Dis. 2009, 42(1):38-43.
16. Exalto L.G., Whitmer R.A., Kappele L.J., Biessels G.J. An update on type 2 diabetes, vascular dementia and Alzheimer's disease. Exp. Gerontol. 2012, 47(11):858-864.
17. Farrer L.A., Cupples L.A., Haines J.L., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. J. Am. Med. Assoc. 1997, 278(16):1349-1356.
18. Fleisher A.S., Chen K., Liu X., et al. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch. Neurol. 2011, 68(11):1404-1411.
19. Graves A.B., Bowen J.D., Rajaram L., et al. Impaired olfaction as a marker for cognitive decline interaction with apolipoprotein E ε4 status. Neurology 1999, 53(7):1480.
20. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65(4):391-426.
21. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 2008, 104(6):1433-1439.
22. Huang C.C., Chung C.M., Leu H.B., et al. Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study. PLoS ONE 2014, 9(1):e87095.
23. Hye A., Kerr F., Archer N., et al. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci. Lett. 2005, 373(1):1-4.
24. Janson J., Laedtke T., Parisi J.E., et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53(2):474-481.
25. Kettunen P., Larsson S., Holmgren S., et al. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function. J. Alzheimers Dis. 2015, 44(4):1313-1322.
26. Kim D.S., Lee H.S., Choi S.I., Suh S.P. Modified and improved ARMS PCR method for apolipoprotein E genotyping. Korean J. Clin. Pathol. 2000, 20(2):150-156.
27. Kovacs T. Mechanisms of olfactory dysfunction in aging and neurodegenerative disorders. Ageing Res. Rev. 2004, 3(2):215-232.
28. Langbaum J.B., Chen K., Lee W., et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's disease neuroimaging initiative (ADNI). NeuroImage 2009, 45(4):1107-1116.
29. Lehrner J., Pusswald G., Gleiss A., Auff E., Dal-Bianco P. Odor identification and self-reported olfactory functioning in patients with subtypes of mild cognitive impairment. Clin. Neuropsychol. 2009, 23(5):818-830.
30. Ma J., Yee A., Brewer H.B., Das S., Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994, 372(6501):92-94.
31. Martin L., Latypova X., Wilson C.M., et al. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res. Rev. 2013, 12(1):289-309.
32. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34(7):939.
33. Naka A., Riedl M., Luger A., Hummel T., Mueller C.A. Clinical significance of smell and taste disorders in patients with diabetes mellitus. Eur. Arch. Otorhinolaryngol. 2010, 267(4):547-550.
34. Olofsson J.K., Nordin S., Wiens S., et al. Odor identification impairment in carriers of ApoE-varepsilon4 is independent of clinical dementia. Neurobiol. Aging 2010, 31(4):567-577.
35. Olokoba A.B., Obateru O.A., Olokoba L.B. Type 2 diabetes mellitus: a review of current trends. Oman Med. J. 2012, 27(4):269-273.
36. Pei J.J., Tanaka T., Tung Y.C., et al. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 1997, 56(1):70-78.
37. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies the Honolulu-Asia aging study. Diabetes 2002, 51(4):1256-1262.
38. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56(3):303-308.
39. Phiel C.J., Wilson C.A., Lee V.M.Y., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423(6938):435-439.
40. Plattner F., Angelo M., Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 2006, 281(35):25457-25465.
41. Rahayel S., Frasnelli J., Joubert S. The effect of Alzheimer's disease and Parkinson's disease on olfaction: a meta-analysis. Behav. Brain Res. 2012, 231(1):60-74.
42. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 2009, 156(6):885-898.
43. Sheng J.H., Ng T.P., Li C.B., et al. The peripheral messenger RNA expression of glycogen synthase kinase-3β genes in Alzheimer's disease patients: a preliminary study. Psychogeriatrics 2012, 12(4):248-254.
44. Strachan M.W., Reynolds R.M., Marioni R.E., Price J.F. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat. Rev. Endocrinol. 2011, 7(2):108-114.
45. Stumvoll M., Goldstein B.J., van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365(9467):1333-1346.
46. Sutton T.A., Sohrabi H.R., Rainey-Smith S.R., et al. The role of APOE-varepsilon4 and beta amyloid in the differential rate of recovery from ECT: a review. Transl. Psychiatry 2015, 5:e539.
47. Tan C.C., Yu J.T., Tan L. Biomarkers for preclinical Alzheimer's disease. J. Alzheimers Dis. 2014, 42(4):1051-1069.
48. Umegaki H. Type 2 diabetes as a risk factor for cognitive impairment: current insights. Clin. Interv. Aging 2014, 9:1011-1019.
49. Vemuri P., Wiste H.J., Weigand S.D., et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann. Neurol. 2010, 67(3):308-316.
50. Vyhnalek M., Magerova H., Andel R., et al. Olfactory identification in amnestic and non-amnestic mild cognitive impairment and its neuropsychological correlates. J. Neurol. Sci. 2015, 349(1-2):179-184.
51. Weisgraber K.H. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 1994, 45:249-302.
52. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9(8):2431-2438.